A Placebo-Controlled, Single and Multiple Dose Study to Investigate the Appropriate Parameters for Evaluation of Pharmacodynamic Equivalence of Voglibose in Healthy Korean Volunteers |
Jang, Kyungho
(Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital)
Cho, Sang-Heon (Department of Clinical Pharmacology, Inha University School of Medicine & Hospital) Kim, Jung-Ryul (Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center) Chung, Jae-Yong (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital) Lim, Kyoung Soo (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) Jang, In-Jin (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) Yu, Kyung-Sang (Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital) |
1 | Ryuzo Kawamori, Naoko Tajima, Yasuhiko Iwamoto, Atsunori Kashiwagi, Kazuaki Shimamoto, Kohei Kaku. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet, 2009;373(9675):1607-1614. DOI |
2 | Kim S.G. Choi D.S. The Present State of Diabetes Mellitus in Korea. J Korean Med Assoc, 2008;51(9):791-798. (Korean) DOI |
3 | Monnier, L., Is postprandial glucose a neglected cardiovascular risk factor in type 2 diabetes? Eur J Clin Invest, 2000;30(2):3-11. DOI |
4 | Ishida, H., [alpha-Glucosidase inhibitor]. Nihon Rinsho, 1999;57(3):669-74. |
5 | KFDA, KFDA web sites on Bioequivalence test information.http://drug.mfds.go.kr/html/men uLinkBody.jsp?p_menuId=0201#1. [Online] (last visited 01 May 2013). |
6 | Ahr HJ, Boberg M, Krause HP, Maul W, Müller FO, Ploschke HJ, Weber H, Wünsche C. Pharmacokinetics of acarbose. Part I: Absorption, concentration in plasma, metabolism and excretion after single administration of [14C]acarbose to rats, dogs and man. Arzneimittel-Forschung, 1989;39(10):1254-1260. |
7 | H. Fuder, P. Kleist, M.Birkel, A. Ehrlich, S. Emeklibas, W. Maslak, E. Stridde, N. Wetzelsberger, G. Wieckhorst, P. W. Lucker. The -glucosidase inhibitor voglibose (AO-128) dose not change pharmacodynamics or pharmacokinetics of warfarin. Eur J Clin Pharmacol, 1997;53:153-157. DOI |
8 | Food and Drug Administration, Center of Drug Evaluation and Research (CDER), Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations, 2003. |
9 | Food and Drug Administration, Center of Drug Evaluation and Research (CDER), Draft Guidance on Acarbose. 2009. |
10 | Bae JW, Jang CG, Lee SY. Methods for pharmacodynamic analysis and proposed protocols for bioequivalence study of acarbose. Yakhak Hoeji, 2007;51(6):440-446. |
11 | kageyama S, Nakamichi N, Sekino H, Fujita H, Nakano S. Comparison of the effects of acarbose and voglibose on plasma glucose, endogenous insulin sparing, and gastrointestinal adverse events in obese subjects: a randomized, placebo-controlled, double-blind, three-way crossover study. Curr Ther Res. 2000;61(9):630-645. DOI |
12 | Min Zhang, Jin Yang, Lei Tao, Lingjun Li, Pengcheng Ma, John Paul Fawcett. Acarbose Bioequivalence: Exploration of New Pharmaco- dynamic Parameters. AAPS J, 2012;14(2):345- 351. DOI |
13 | Lee S, Chung JY, Hong KS, Yang SH, Byun SY, Lim HS, Shin SG, Jang IJ, Yu KS. Pharmacodynamic comparison of two formulations of Acarbose 100-mg tablets. J Clin Pharm Ther, 2012;37(5):553-557. DOI |
14 | Kageyama S, Nakamichi N, Sekino H, Nakano S. Comparison of the effects of acarbose and voglibose in healthy subjects. Clin Thera, 1997;19(4):720-729. DOI |
15 | Food and Drug Administration, Center of Drug Evaluation and Research (CDER), Guidance for Industry: Diabetes Mellitus:Developing Drugs and Therapeutic Biologics for Treatment and Prevention (Draft). 2008. |
16 | John WG, Hillson R, Alberti SG, Use of haemoglobinA1c (HbA1c) in the diagnosis of diabetes mellitus. The implementation of World Health Organisation WHO guidance 2011. Practical Diabetes, 2012;29(1):12-12a. DOI |